Bio-Techne

Update in progress

TECH (NasdaqGS)

Company RatingNeutral
SectorHealthcare
IndustryBiotechnology

Bio-Techne Corporation and its subsidiaries develop, manufacture, and sell life science reagents, instruments, and services for research, diagnostics, and bioprocessing worldwide. It operates in two segments: Protein Sciences, providing proteins, antibodies, cytokines, growth factors, small molecules, sera, and proteomics tools; and Diagnostics and Spatial Biology, offering diagnostic kits, controls, exosome assays, in situ hybridization, genetic/oncology assays, and related instruments. Incorporated 1976, formerly Techne, based in Minneapolis.

Company score

Sentiment: 0.31; SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
Environment: -0.12; EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
Social: 0.26; SocialAssesses the company’s influence on employees, customers, communities, and wider society.−10 negative · 0 neutral · +10 positive
Governance: 0.11; GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
Sustainability: 0.06; SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
Impact Score: 0.19; Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive